nPhase launched an AI platform aimed at accelerating regulatory submission preparation for clinical trials, claiming it can convert raw study data into submission-ready materials 75% to 80% faster than traditional workflows. The platform targets a key bottleneck for sponsors—turning diverse datasets into structured, documentation-complete regulatory packages. The company’s pitch centers on efficiency gains without changing the underlying need for compliance-grade outputs, positioning the tool for teams managing complex clinical data pipelines across trial operations and regulatory affairs. As clinical development timelines tighten and data volumes expand, submission automation is becoming a competitive differentiator—particularly for mid-stage biotechs that rely on streamlined execution to preserve runway.